O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies

[1]  H. Einsele,et al.  Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. , 2015, Blood.

[2]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[3]  C. Srisomsap,et al.  Alteration of O-GlcNAcylation affects serine phosphorylation and regulates gene expression and activity of pyruvate kinase M2 in colorectal cancer cells. , 2015, Oncology reports.

[4]  J. Snowden,et al.  The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours , 2015, British Journal of Cancer.

[5]  David L Porter,et al.  CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. , 2015, Blood.

[6]  S. Hubbard,et al.  Molecular insights into regulation of JAK2 in myeloproliferative neoplasms. , 2015, Blood.

[7]  B. Groner,et al.  Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells , 2015, Cancers.

[8]  S. Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[9]  María Martín,et al.  UniProt: A hub for protein information , 2015 .

[10]  Can Alkan,et al.  Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells , 2015, Nature Communications.

[11]  Albrecht Reichle,et al.  Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Martin,et al.  Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. , 2014, Cell reports.

[13]  V. Champattanachai,et al.  Aberrant O-GlcNAcylated Proteins: New Perspectives in Breast and Colorectal Cancer , 2014, Front. Endocrinol..

[14]  The Uniprot Consortium,et al.  UniProt: a hub for protein information , 2014, Nucleic Acids Res..

[15]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[16]  G. Hart,et al.  Nutrient regulation of signaling, transcription, and cell physiology by O-GlcNAcylation. , 2014, Cell metabolism.

[17]  Marco Biasini,et al.  SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information , 2014, Nucleic Acids Res..

[18]  C. Pecquet,et al.  Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation , 2014, Oncogene.

[19]  Junfeng Ma,et al.  O-GlcNAc profiling: from proteins to proteomes , 2014, Clinical Proteomics.

[20]  B. Groner,et al.  Cytokine regulation of mammary gland development and epithelial cell functions through discrete activities of Stat proteins , 2014, Molecular and Cellular Endocrinology.

[21]  C. Srisomsap,et al.  Aberrant O-GlcNAc-modified proteins expressed in primary colorectal cancer. , 2013, Oncology reports.

[22]  Iris Z. Uras,et al.  PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis , 2013, Leukemia.

[23]  J. Wolchok,et al.  Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.

[24]  I. Mills,et al.  O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. , 2013, Cancer research.

[25]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[26]  H. Kantarjian,et al.  Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia , 2013, Cancer.

[27]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[28]  K. Kreuzer,et al.  Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. , 2012, Blood.

[29]  R. Moriggl,et al.  Acetylation and sumoylation control STAT5 activation antagonistically , 2012, JAK-STAT.

[30]  Andreas Wolf,et al.  Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. , 2012, Blood.

[31]  Bernhard Kuster,et al.  Discovery of O-GlcNAc-modified Proteins in Published Large-scale Proteome Data* , 2012, Molecular & Cellular Proteomics.

[32]  Anthony R Green,et al.  Janus kinase deregulation in leukemia and lymphoma. , 2012, Immunity.

[33]  Clifford Liongue,et al.  Evolution of JAK-STAT Pathway Components: Mechanisms and Role in Immune System Development , 2012, PloS one.

[34]  G. Superti-Furga,et al.  BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. , 2012, Nature chemical biology.

[35]  K. Kretschmer,et al.  Retargeting of Human Regulatory T Cells by Single-Chain Bispecific Antibodies , 2012, The Journal of Immunology.

[36]  N. Speybroeck.  Classification and regression trees , 2012, International Journal of Public Health.

[37]  M. Levings,et al.  Suppression assays with human T regulatory cells: A technical guide , 2012, European journal of immunology.

[38]  T. Mcclanahan,et al.  IL-10 elicits IFNγ-dependent tumor immune surveillance. , 2011, Cancer cell.

[39]  Bin Zhang,et al.  PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse , 2011, Nucleic Acids Res..

[40]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[41]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[42]  H. Kantarjian,et al.  Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration , 2010, Cancer.

[43]  H. Coller,et al.  The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. , 2010, Genes & development.

[44]  H. Beug,et al.  Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. , 2010, Blood.

[45]  J. Dennis,et al.  Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia , 2010, Leukemia.

[46]  G. Sethi,et al.  Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1 , 2010, Oncogene.

[47]  Sreenath S. Andrali,et al.  Modulation of transcription factor function by O-GlcNAc modification. , 2010, Biochimica et biophysica acta.

[48]  M. Tormo,et al.  Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group , 2010, Haematologica.

[49]  G. Hart,et al.  The intersections between O-GlcNAcylation and phosphorylation: implications for multiple signaling pathways , 2010, Journal of Cell Science.

[50]  L. Hennighausen,et al.  Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. , 2009, Blood.

[51]  W. Tse,et al.  STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease. , 2009, Blood.

[52]  Torsten Schwede,et al.  Automated comparative protein structure modeling with SWISS‐MODEL and Swiss‐PdbViewer: A historical perspective , 2009, Electrophoresis.

[53]  H. Kantarjian,et al.  Outcome of adults with acute lymphocytic leukemia after second salvage therapy , 2008, Cancer.

[54]  Torsten Schwede,et al.  The SWISS-MODEL Repository and associated resources , 2008, Nucleic Acids Res..

[55]  G. Hart,et al.  Regulation of the O-Linked β-N-Acetylglucosamine Transferase by Insulin Signaling* , 2008, Journal of Biological Chemistry.

[56]  D. Vignali,et al.  How regulatory T cells work , 2008, Nature Reviews Immunology.

[57]  L. Kenner,et al.  The different functions of Stat5 and chromatin alteration through Stat5 proteins. , 2008, Frontiers in bioscience : a journal and virtual library.

[58]  U. Klingmüller,et al.  Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. , 2008, Blood.

[59]  T. Ley,et al.  Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. , 2007, Immunity.

[60]  H. Dombret,et al.  Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial , 2007, Leukemia.

[61]  K. D. Bunting,et al.  STAT5 signaling in normal and pathologic hematopoiesis. , 2007, Frontiers in bioscience : a journal and virtual library.

[62]  B. Chauffert,et al.  Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients , 2007, Cancer Immunology, Immunotherapy.

[63]  Shimon Sakaguchi,et al.  Natural regulatory T cells: mechanisms of suppression. , 2007, Trends in molecular medicine.

[64]  C. Pecquet,et al.  Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. , 2007, Blood.

[65]  Rajesh Chopra,et al.  Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.

[66]  J. Ihle,et al.  A role for STAT5A/B in protection of peripheral T-lymphocytes from postactivation apoptosis: insights from gene expression profiling. , 2006, Cytokine.

[67]  Torsten Schwede,et al.  BIOINFORMATICS Bioinformatics Advance Access published November 12, 2005 The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling , 2022 .

[68]  Roman K. Thomas,et al.  Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. , 2005, Blood.

[69]  T. Ley,et al.  Human T regulatory cells can use the perforin pathway to cause autologous target cell death. , 2004, Immunity.

[70]  G. Hart,et al.  The Coactivator of Transcription CREB-binding Protein Interacts Preferentially with the Glycosylated Form of Stat5* , 2004, Journal of Biological Chemistry.

[71]  H. Nawata,et al.  TGF-β1 Plays an Important Role in the Mechanism of CD4+CD25+ Regulatory T Cell Activity in Both Humans and Mice , 2004, The Journal of Immunology.

[72]  D. Levy,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[73]  Fengxue Zhang,et al.  Alloxan is an inhibitor of the enzyme O-linked N-acetylglucosamine transferase. , 2002, Biochemical and biophysical research communications.

[74]  S. Bhattacharya,et al.  Signaling through the JAK/STAT pathway, recent advances and future challenges. , 2002, Gene.

[75]  M. Nowicki,et al.  Correlation between Early Treatment Failure and Ki67 Antigen Expression in Blast Cells of Children with Acute Lymphoblastic Leukaemia before Commencing Treatment , 2002, Oncology.

[76]  Ana Cumano,et al.  CD25+ CD4+ T Cells Regulate the Expansion of Peripheral CD4 T Cells Through the Production of IL-101 , 2001, The Journal of Immunology.

[77]  J. Ihle,et al.  Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. , 1999, Immunity.

[78]  J. Darnell,et al.  Structure of the amino-terminal protein interaction domain of STAT-4. , 1998, Science.

[79]  G. Hart,et al.  Glycosylation of the c-Myc transactivation domain. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[80]  B. Groner,et al.  Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. , 1994, The EMBO journal.

[81]  M. Quinn,et al.  Low dose cyclophosphamide: Mechanisms of T cell modulation. , 2016, Cancer treatment reviews.

[82]  R. Larson,et al.  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. , 2015, The Lancet. Oncology.

[83]  A. Liston,et al.  Regulatory T Cells , 2011, Methods in Molecular Biology.

[84]  E. Wagner,et al.  Stat5 tetramer formation is associated with leukemogenesis. , 2005, Cancer cell.

[85]  E. Balcerczak,et al.  Some oncogene and tumour suppressor gene protein products expression in B-cell chronic lymphocytic leukaemia. , 2000, Cytobios.

[86]  R. Fisher,et al.  The Logic of Inductive Inference , 1935 .

[87]  H. Berman,et al.  The Protein Data Bank. , 2002, Acta crystallographica. Section D, Biological crystallography.

[88]  Can Alkan,et al.  Activating mutations of STAT5B and STAT3 in lymphomas derived from gamma delta-T or NK cells , 2022 .